Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exelixis, Inc.    EXEL

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company returns high margins, thereby supporting business profitability.
  • The group usually releases upbeat results with huge surprise rates.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • With an enterprise value anticipated at 5.44 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 75.87 times its estimated earnings per share for the ongoing year.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
EXELIXIS, INC.10.31%6 869
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148
GENMAB A/S7.31%28 292
BIONTECH SE33.02%26 111
ARGENX SE5.21%14 672
HUALAN BIOLOGICAL ENGINEERI..21.69%14 468
MYOKARDIA, INC.0.00%11 993
-
NEUROCRINE BIOSCIENCES, INC..19.98%10 923
MIRATI THERAPEUTICS, INC.-2.36%10 783
DENALI THERAPEUTICS INC.-5.53%9 489
ULTRAGENYX PHARMACEUTICAL I..1.47%9 293
FATE THERAPEUTICS, INC.6.88%8 909
More Results
Financials (USD)
Sales 2020 988 M - -
Net income 2020 99,7 M - -
Net cash 2020 1 494 M - -
P/E ratio 2020 75,9x
Yield 2020 -
Capitalization 6 869 M 6 869 M -
EV / Sales 2020 5,44x
EV / Sales 2021 4,23x
Nbr of Employees 617
Free-Float 98,0%
Upcoming event on EXELIXIS, INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes